Highlights
In patients with stable atherosclerotic cardiovascular disease (ASCVD), every 5-unit increase in Body Mass Index (BMI) above 30 kg/m2 is associated with an 11% higher risk of major adverse cardiovascular events (MACE).
The relative risk reduction (RRR) for the primary cardiovascular endpoint with evolocumab was progressively greater in patients with higher BMI, reaching 29% in those with a BMI of 35 kg/m2 or higher.
